BioDelivery (BDSI) Q4 Earnings And Revenues Beat Estimates

By Zacks Investment ResearchStock MarketsMar 12, 2020 09:29PM ET

www.investing.com/analysis/biodelivery-bdsi-q4-earnings-and-revenues-beat-estimates-200515801

BioDelivery (BDSI) Q4 Earnings And Revenues Beat Estimates

By Zacks Investment Research | Mar 12, 2020 09:29PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

VRTX

+0.73%

Add to/Remove from Watchlist

BDSI

0.00%

Add to/Remove from Watchlist

ENDPQ

0.00%

Add to/Remove from Watchlist

REGN

-1.99%

Add to/Remove from Watchlist

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) recorded adjusted earnings of 6 cents per share for fourth-quarter 2019, which beat the Zacks Consensus Estimate of loss of a cent. In the year-ago quarter, the company had incurred an adjusted loss of 7 cents per share.

Revenues totaled $31.6 million, up 75.6% from the year-ago period and 4.3% sequentially. Sales also outpaced the Zacks Consensus Estimate of $31.26 million. The uptick was mainly driven by higher sales of Belbuca and the addition of Symproic tablets to its portfolio. The company added Symproic to its portfolio by acquiring U.S. commercial rights to the drug from Japan-based pharma company, Shionogi, in April 2019.

In the past year, shares of BioDelivery have declined 18.6% compared with the industry’s 16% decrease.

Quarter in Detail

BioDelivery’s marketed portfolio included Belbuca for chronic pain, Bunavail for treating opioid dependence and Symproic for opioid-induced constipation. The company announced the discontinuation of marketing of Bunavail earlier this month.

Belbuca, generated revenues of $28.3 million in the quarter, up 6.8% sequentially. On a year-over-year basis, the top line soared 78%. Sales of the drug have been witnessing a strong uptrend since 2018. Notably, the company re-acquired worldwide rights to the drug in early 2017 from Endo International (NASDAQ:ENDP) .

BioDelivery recorded Belbuca prescriptions of more than 96,000 for the quarter, representing a prescription volume growth of more than 70% in the quarter. This was the highest ever year over year growth for any three-month period.

Symproic sales in the fourth quarter were $2.7 million, up 22.7% sequentially. Total Symproic prescriptions during the quarter were 16,555, which reached an all-time high and represented more than 36% growth from the prior-year period.

Sales of Bunavail, indicated for the treatment of opioid dependence, were negative $0.5 million in the fourth quarter, compared to $1.2 million in the year-ago quarter. Negative sales of the drug during the quarter were due to one-time costs related to its discontinuation.

Product Royalty revenues in the fourth quarter were $1.2 million compared with $1 million in the year-ago period.

2019 Results

BioDelivery reported total revenues of $111.4 million, up 100% year over year. Adjusted earnings for the full year were 16 cents per share against an adjusted loss of 34 cents in 2018. Belbuca sales were up 112% year over year.

BioDelivery Sciences International, Inc. Price, Consensus and EPS Surprise

BioDelivery Sciences International, Inc. Price, Consensus and EPS Surprise

BioDelivery Sciences International, Inc. price-consensus-eps-surprise-chart | BioDelivery Sciences International, Inc. Quote

Zacks Rank & Other Key Picks

BioDelivery currently carries a Zacks Rank #2 (Buy).

A couple of other stocks to consider from the biotech sector are Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) . While Regeneron sports a Zacks Rank #1 (Strong Buy), Vertex carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Regeneron’s earnings estimates have moved up from $26.83 to $28.73 for 2020 and from $28.09 to $30.20 for 2021 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with the average beat being 1.44%. Share price of the company has increased 5.6% in the past year.

Vertex’s earnings estimates have moved up from $6.68 to $7.57 for 2020 and from $8.61 to $9.62 for 2021 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average beat being 21.76%. Share price of the company has increased 9.9% in the past year.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>

Endo International plc (ENDP): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report

Original post

Zacks Investment Research

Why Intel 18A Is a Make-or-Break Moment for the Chipmaker By Timothy Fries - Mar 03, 2025 1

Two weeks ago, the rumor mill ramped up again about the potential restructuring of Intel Corporation (NASDAQ:INTC). The probing balloons centered around Taiwan Semiconductor...

Trade Wars Come With a Price, and Investors May Already Be Paying It By Frank Holmes - Mar 03, 2025 4

More than a century ago, then-Representative William McKinley pursued an aggressive tariff strategy that sought to protect American industry and reduce reliance on foreign...

1 Value, 1 Growth, and 1 Momentum Stock for Diversification By Nathan Reiff - Mar 03, 2025

Early in 2025, value stocks emerged as a popular choice among investors seeking market-beating returns. However, factor-based investing strategies can be notoriously difficult to...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	43,258.0	+66.0	+0.15%
US 500	5,867.6	+17.7	+0.30%
Dow Jones	43,191.24	-649.67	-1.48%
S&P 500	5,849.72	-104.78	-1.76%
Nasdaq	18,350.19	-497.09	-2.64%
S&P 500 VIX	22.78	+0.00	+0.00%
Dollar Index	106.520	-0.149	-0.14%

Crude Oil WTI	67.90	-0.47	-0.69%
Brent Oil	70.98	-0.64	-0.89%
Natural Gas	4.107	-0.057	-1.37%
Gold	2,901.22	+0.12	+0.00%
Silver	32.290	-0.020	-0.06%
Copper	4.5893	-0.0015	-0.03%
US Soybeans	1,008.88	-1.88	-0.19%

U.S. 10Y	4.149	-0.031	-0.74%
U.S. 30Y	4.458	-0.006	-0.13%
U.S. 5Y	3.953	-0.036	-0.90%
U.S. 3M	4.310	+0.006	+0.14%
US 10Y T-Note	111.59	+0.22	+0.20%
Euro Bund	131.52	+0.41	+0.31%
10-2 Yield Spread	21.37	+0.32	+1.52%

Apple	238.03	-3.81	-1.58%
Alphabet A	167.01	-3.27	-1.92%
Tesla	284.65	-8.33	-2.84%
Amazon.com	205.02	-7.26	-3.42%
Netflix	973.70	-6.86	-0.70%
Meta Platforms	655.05	-13.15	-1.97%
Bank of America	45.56	-0.54	-1.17%

BioDelivery (BDSI) Q4 Earnings And Revenues Beat Estimates

Related Articles